• share
• favorite_border

• share
• favorite_border

New York, NY [January 4, 2023]—In a milestone study, researchers from the Icahn School of Medicine at Mount Sinai have harnessed the power of artificial intelligence (AI) to enhance the assessment of the heart’s right ventricle, which sends blood to the lungs.

• share
• favorite_border

Mount Sinai researchers have shown for the first time that a person’s beliefs related to drugs can influence their own brain activity and behavioral responses in a way comparable to the dose-dependent effects of pharmacology.

• share
• favorite_border

Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score. The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2]. Studies have shown that drugs have an increased likelihood of success in clinical trials when the genes they target have been demonstrated to have genetic support. The new tool integrates multiple lines of genetic evidence to prioritize these drug targets.

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway. Their findings, detailed in the January 2 online issue of Nature Communications https://doi.org/10.1038/s41467-023-44601-4, show that a brain protein known as the TAAR1 receptor, a drug target known to regulate dopamine signaling in key reward pathways in the brain, differs significantly in humans compared to the preclinical rodent models on which drugs are typically tested. The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.

• share
• favorite_border

Patient-specific mutation-engineered mouse reveals how sensory neurons may trigger some allergy conditions but block others, suggesting more precise design of JAK inhibitors is necessary.

• share
• favorite_border

Prestigious grant will allow the New York City Virus Hunters initiative to expand an ongoing collaboration with BioBus that enables young students to keep city safe and help avoid future pandemics.

• share
• favorite_border

In a novel study, researchers from the Icahn School of Medicine at Mount Sinai introduced LoGoFunc, an advanced computational tool that predicts pathogenic gain- and loss-of-function variants across the genome.

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC). And in an early parallel study in humans, combining immunotherapy with dupilumab—an Interleukin-4 (IL-4) receptor-blocking antibody widely used for treating allergies and asthma—boosted patients' immune systems, with one out of the six experiencing significant tumor reduction. The findings were described in the December 6 issue of Nature.

• share
• favorite_border

Awarded $4 million in NIH grants to study new therapies for improved survival

• share
• favorite_border

A new analysis of the brain activity of people with post-traumatic stress disorder (PTSD) is the first to reveal that traumatic memories are represented in the brain in an entirely different way than sad autobiographical memories.

• share
• favorite_border

• share
• favorite_border

Nationally recognized leader in academic medicine, delivering high-quality health care as a physician, health policy researcher, and educator

• share
• favorite_border

• share
• favorite_border

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

• share
• favorite_border

Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN, has been appointed as the new Dean of the Mount Sinai Phillips School of Nursing.

• share
• favorite_border

Findings will help scientists understand how microgravity impacts the ability of human heart cells to withstand the stresses of space travel

• share
• favorite_border

Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer. The study, published in Genome Research, serves as a comprehensive resource and lays the foundation for the development of next-generation cancer treatments and diagnostic markers.

• share
• favorite_border

Introducing the Allen Discovery Center for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai, Co-Led by Weill Cornell Medicine

• share
• favorite_border

Mount Sinai researchers have shed valuable light on the mechanism of a key protein that regulates the plasticity and function of the hippocampus, a key brain region involved in memory and learning, and that decreases with age in mice.

• share
• favorite_border

Mount Sinai-led study is the first to show there are no sex disparities in patient outcomes with this new technology

• share
• favorite_border

The Icahn School of Medicine at Mount Sinai will award its 2023 Maria I. New International Prize for Biomedical Research to Jean-Laurent Casanova, MD, PhD, for revolutionizing our understanding of human infectious diseases through the discovery of genetic and immunological determinants that underpin both rare and common infectious illnesses. The prize honors medical pioneers in the tradition of Maria I. New, MD, a world-renowned researcher in pediatric genetic disorders with a special focus on endocrinology over her six-decade career. Dr. Casanova will receive a prize of $20,000 and will present the Maria I. New Distinguished Lecture during a ceremony to be held in at Icahn Mount Sinai in New York City on November 21, 2023.

• share
• favorite_border

The largest brain autopsy study of women who had experienced intimate partner violence reveals substantial vascular and white matter damage in the brain, but no evidence of chronic traumatic encephalopathy (CTE), the neurodegenerative disease recognized among male contact sports athletes who sustain repeated head trauma.

• share
• favorite_border

“Mount Sinai Fuster Heart Hospital” furthers vision of world-leading cardiac care and research that prevents heart disease worldwide

• share
• favorite_border

A Mount Sinai-led team of researchers has shed new light on the ways in which cocaine addiction dysregulates the normal function of dopamine neurons and thus the brain’s ability to process and respond to reward-related information, making it more difficult for individuals to change their addictive behaviors.

• share
• favorite_border

Models built on machine learning in health care can be victims of their own success, according to researchers at the Icahn School of Medicine and the University of Michigan.

• share
• favorite_border

Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.

• share
• favorite_border

Today, the Mount Sinai Health System, New York City’s largest academic medical system, announced the opening of its new Discovery and Innovation Center with a ceremonial ribbon cutting. This state-of-the-art research lab will expand research capabilities in collaboration with clinical neuroscience and neurosurgery centers of excellence at Mount Sinai West.